CEO Jacqui Shea highlighted that Inovio remains committed to transforming into a commercial-stage company, with a primary focus on advancing INO-3107, a DNA medicine for recurrent respiratory ...

PLYMOUTH MEETING, Pa., Nov. 13, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from ...

CEO Jacqueline Shea highlighted that "these are very exciting times for Inovio with our first BLA for INO-3107 as a potential treatment for adults with recurrent respiratory papillomatosis or RRP, ...

CEO Jacqueline Shea highlighted, “we have achieved our primary objective for this year, which is completing the rolling submission of our BLA for INO-3107. This represents a milestone in our work to ...

Company will request Rolling Submission and Priority Review of its Biological License Application (BLA) by U.S. Food and Drug Administration (FDA) to expedite review process Accelerating ...

Expect to receive file acceptance by year end 2025 with potential PDUFA date in mid-2026 if request for priority review granted PLYMOUTH MEETING, Pa., Nov. 3, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO) ...

Retrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compared to 72% observed at the end of the initial 12-month Phase 1/2 trial ...

Credit: Shutterstock. Recurrent respiratory papillomatosis is caused primarily by HPV types 6 and 11. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to INO-3107 ...

PLYMOUTH MEETING, Pa. - INOVIO (NASDAQ: INO), a pioneer in the development of DNA medicines, announced today that its lead candidate INO-3107 has received certification from the European Medicines ...

Inovio, a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, announced that the ...